Delayed thrombin generation with hirudin anticoagulation during prolonged cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 79, Issue 1, 2005, Pages 334-336

  Rubens, Fraser D ^a,c   Lavalee, Gilbert ^b   Ruel, Marc A ^a   Mesana, Thierry ^a   Bourke, Michael ^c  

^a Division of Cardiac Surgery   (Canada)

^b Division of Perfusion   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

25

Indexed keywords

DANAPAROID; LEPIRUDIN; WARFARIN;

AGED; ANAMNESIS; ANTICOAGULATION; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DRUG EFFICACY; FEMALE; HUMAN; INFORMED CONSENT; LABORATORY TEST; LUNG EMBOLISM; MEDICAL EXAMINATION; PATIENT REFERRAL; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; SURGICAL TECHNIQUE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; CHONDROITIN SULFATES; DERMATAN SULFATE; ENDARTERECTOMY; FEMALE; HEPARIN; HEPARITIN SULFATE; HIRUDINS; HUMANS; HYPERTENSION, PULMONARY; PLASMA; PLATELET TRANSFUSION; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; THROMBECTOMY; THROMBIN; THROMBOCYTOPENIA; TIME FACTORS; WARFARIN;

EID: 11144280622     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)01658-8     Document Type: Article

References (11)

1. Furukawa K., Ohteki H., Hirahara K., Narita Y., Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg. 122:2001;1255-1256
2. Koster A., Kuppe H., Hetzer R., Sodian R., Crystal G.J., Mertzlufft F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology. 89:1998;777-780
3. Rubens F.D., Sabloff M., Wells P.S., Bourke M. Use of recombinant-hirudin in pulmonary thromboendarterectomy. Ann Thorac Surg. 69:2000;1942-1943
4. Koster A., Hansen R., Kuppe H., Hetzer R., Crystal G.J., Mertzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth. 14:2000;243-248
5. Kappa J.R., Fisher C.A., Todd B., et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg. 49:1990;714-722
6. Jamieson S.W., Auger W.R., Fedullo P.F., et al. Experience and results of 150 pulmonary thromboendarterectomy operations over a 29 month period. J Thorac Cardiovasc Surg. 106:1993;116-127
7. Koster A., Loebe M., Hansen R., et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II adaptation of the ecarin clotting time to the ACT II device. J Thorac Cardiovasc Surg. 119:2000;1278-1283
8. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemostas. 66:1991;141-152
9. Fenton J.W., Villanueva G.B., Ofosu F.A., Maraganore J.M. Thrombin inhibition by hirudin how hirudin inhibits thrombin. Haemostasis. 21:1991;27-31
10. Zoldhelyi P., Bichler J., Owen W.G., et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation. 90:1994;2671-2678
11. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochem. 25:1986;4622-4628